Translate Bio, Inc. (TBIO): Price and Financial Metrics

Translate Bio, Inc. (TBIO)

Today's Latest Price: $22.01 USD

0.49 (-2.18%)

Updated Dec 3 1:01pm

Add TBIO to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 389 in Biotech

See all "A" rated Strong Buy stocks

TBIO Stock Summary

  • Translate Bio Inc's stock had its IPO on June 28, 2018, making it an older stock than just 6.47% of US equities in our set.
  • With a year-over-year growth in debt of 414.43%, Translate Bio Inc's debt growth rate surpasses 95.75% of about US stocks.
  • As for revenue growth, note that TBIO's revenue has grown 1,691.78% over the past 12 months; that beats the revenue growth of 99.53% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to Translate Bio Inc, a group of peers worth examining would be RCUS, RGNX, CRUS, MORF, and SMCI.
  • Visit TBIO's SEC page to see the company's official filings. To visit the company's web site, go to

TBIO Stock Price Chart Interactive Chart >

Price chart for TBIO

TBIO Price/Volume Stats

Current price $22.01 52-week high $28.09
Prev. close $22.50 52-week low $6.80
Day low $21.79 Volume 440,435
Day high $22.75 Avg. volume 1,046,907
50-day MA $15.58 Dividend yield N/A
200-day MA $14.46 Market Cap 1.64B

Translate Bio, Inc. (TBIO) Company Bio

Translate Bio, Inc., a messenger RNA therapeutics company, engages in developing medicines to treat diseases caused by protein or gene dysfunction. It is developing MRT5005 that is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 for the treatment of ornithine transcarbamylase deficiency. It has strategic alliances with Sanofi Pasteur. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. was founded in 2011 and is based in Lexington, Massachusetts.

TBIO Latest News Stream

Event/Time News Detail
Loading, please wait...

TBIO Latest Social Stream

Loading social stream, please wait...

View Full TBIO Social Stream

Latest TBIO News From Around the Web

Below are the latest news stories about Translate Bio Inc that investors may wish to consider to help them evaluate TBIO as an investment opportunity.

Translate Bio, Sanofi COVID-19 vaccine candidate produces immune response in animal studies

Translate Bio Inc said on Tuesday that an experimental coronavirus vaccine it developed with French drugmaker Sanofi SA induced immune response in non-human studies, with trials in humans expected to start in November.

Reuters | August 25, 2020

Translate Bio (TBIO) Investor Presentation - Slideshow

The following slide deck was published by Translate Bio, Inc. in conjunction with this event....

SA Transcripts on Seeking Alpha | August 9, 2020

Translate Bio EPS misses by $0.17, beats on revenue

Translate Bio (TBIO): Q2 GAAP EPS of -$0.58 misses by $0.17.Revenue of $16.32M (+1294.9% Y/Y) beats by $13.5M.Shares -0.13% AH.Press Release...

Seeking Alpha | August 6, 2020

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Translate Bio, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)---- $TBIO #TBIO--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Translate Bio, Inc.

Business Wire | July 31, 2020

Has Translate Bio (TBIO) Outpaced Other Medical Stocks This Year?

Is (TBIO) Outperforming Other Medical Stocks This Year?

Yahoo | July 30, 2020

Read More 'TBIO' Stories Here

TBIO Price Returns

1-mo 63.76%
3-mo 73.58%
6-mo 48.02%
1-year 121.43%
3-year N/A
5-year N/A
YTD 170.39%
2019 8.53%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7067 seconds.